Table 2.
Time-to-event analyses: Cox PH models of mortality and hospitalization
| |
Death |
Hospitalization |
||
|---|---|---|---|---|
| Adjusted hazard ratio | p-value | Adjusted hazard ratio | p-value | |
| Azacitidinea |
0.721 |
(0.008)** |
0.787 |
(0.020)* |
| Age |
1.031 |
(0.000)** |
0.999 |
(0.818) |
| Gender Male |
1.522 |
(0.001)** |
1.097 |
(0.372) |
| Prior Diagnosis of MDSb |
0.878 |
(0.283) |
1.131 |
(0.225) |
| Charlson comorbidity index scorec |
0.937 |
(0.088) |
1.001 |
(0.974) |
| Prior RBC transfusiond |
1.373 |
(0.018)* |
1.321 |
(0.012)* |
| Medicare Advantage enrolleee |
0.973 |
(0.855) |
0.993 |
(0.954) |
| Prior Hospitalizationf |
1.303 |
(0.069) |
1.061 |
(0.618) |
| Observations | 487 | 487 | ||
p-values in parentheses.
*significant at 5%; ** significant at 1%.
Reference groups: adecitabine, bno diagnosis of MDS in the 6 months prior to starting treatment with a demethylating agent, cCharlson comorbidity index is a continuous score from 0 to 24 (most comorbidity burden), dno RBC transfusion in 6 months prior to starting treatment with a demethylating agent, ecommerical insurance, fno hospitalizations in 6 months prior to starting treatment with a demethylating agent.